ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VXRT Vaxart Inc

0.6299
-0.12 (-16.00%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vaxart Inc NASDAQ:VXRT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.12 -16.00% 0.6299 0.59 0.6825 0.78 0.56 0.7523 63,905,608 05:00:09

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23/05/2024 9:01pm

GlobeNewswire Inc.


Vaxart (NASDAQ:VXRT)
Historical Stock Chart


From Jun 2024 to Jun 2024

Click Here for more Vaxart Charts.

Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.

The awards made are as follows: (i) an option to purchase 15,000 shares of Vaxart’s common stock, which vests as to 1/4th of the total shares on the one-year anniversary of the grant date of May 17, 2024, and as to 1/48th of the total shares on each month thereafter, and has a per share exercise price equal to the closing price of Vaxart’s common stock on the grant date; and (ii) a restricted stock unit award covering 7,500 shares of Vaxart’s common stock, which vests as to 25% of the shares underlying the award on the first, second, third and fourth anniversary of the grant date of May 17, 2024.

The awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment “inducement award” pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Vaxart (or following a bona fide period of non-employment) as an inducement material to entering into employment with Vaxart.

About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations:Mark HerrVaxart, Inc.mherr@vaxart.com(203) 517-8957

Investor Relations:Andrew BlazierFINN PartnersIR@vaxart.com(646) 871-8486

1 Year Vaxart Chart

1 Year Vaxart Chart

1 Month Vaxart Chart

1 Month Vaxart Chart

Your Recent History

Delayed Upgrade Clock